Clinical trials: Insufficient Metabolic Control
Diabetes Mellitus, Type 2
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
The study is a comparison of twice-daily insulin lispro low mixture versus once-daily basal insulin glargine and once-daily prandial insulin lispro, in participants with Type 2 Diabetes.
- Trial name
- NCT01175824
- Testing
- Insulin Lispro Low Mixture (LM), Insulin Glargine, Prandial Insulin Lispro
- Where
- 18 sites in Argentina, Brazil and 6 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus (T2DM)
A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus
This is a multicenter, randomized, open-label, positive controlled efficacy exploration study. To compare the efficacy and safety of once-weekly GZR102 Injection and Bi-Weekly GZR18 Injection in Chinese adult subjects with type 2…
- Trial name
- NCT07055386
- Testing
- GZR102, GZR18
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
The objective of the study is to investigate the long-term safety and efficacy of BI 10773 given for 52 weeks as add-on therapy to one oral antidiabetic drug in patients with type 2 diabetes mellitus with insufficient glycaemic…
- Trial name
- NCT01368081
- Testing
- Metformin, BI 10773
- Where
- 87 sites in Japan
- Volunteers
- 1,162 people
- Sponsor
- Boehringer Ingelheim
T2DM (Type 2 Diabetes Mellitus)
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
This double-masked placebo-controlled study will include approximately 450 subjects with inadequately controlled T2DM on diet control alone or on diet control and metformin monotherapy.
- Trial name
- NCT04754334
- Testing
- ORMD-0801
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Oramed, Ltd.
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment in monotherapy in patients with…
- Trial name
- NCT01214239
- Testing
- Linagliptin
- Where
- 19 sites in China, Malaysia and 1 more
- Volunteers
- 300 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- NCT03842267
- Testing
- Gemigliptin 50mg
- Where
- South Korea
- Volunteers
- 315 people
- Sponsor
- LG Chem
Obesity; Drug
Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control
This is a randomized, open, controlled and single-site clinical trail to investigate the effect and safety of Benaglutide or Metformin in patients with simple obesity who have inadequate weight control.
- Trial name
- NCT03593668
- Testing
- Metformin, Benaglutide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Diabetes Mellitus, Type 2
Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (Linagliptin) (5 mg / once daily) compared to placebo given for 24 weeks as initial combination therapy with pioglitazone 30 mg…
- Trial name
- NCT00641043
- Testing
- Linagliptin + pioglitazone (30 mg)
- Where
- 43 sites in Austria, Greece and 5 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.
- Trial name
- NCT00432276
- Testing
- Alogliptin, Pioglitazone, Metformin
- Where
- 86 sites in United States
- Volunteers
- 803 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)
A study to assess the safety and efficacy of MK8245 as monotherapy compared to placebo.
- Trial name
- NCT00846391
- Testing
- MK8245 5 mg (twice a day) b.i.d., MK8245 50 mg b.i.d.
- Volunteers
- 14 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Add-on to Thiazolidinedione (TZD) Failures
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone.
- Trial name
- NCT00683878
- Testing
- Dapagliflozin, Thiazolidinedione (Pioglitazone)
- Where
- 89 sites in United States, Argentina and 7 more
- Volunteers
- 972 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using…
- Trial name
- ACHIEVE-2 (NCT06192108)
- Testing
- Orforglipron, Dapagliflozin
- Where
- 74 sites in United States, China and 4 more
- Volunteers
- 962 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
This study is a multicenter, randomized, double-blind (with open-label dose levels and active comparator), parallel-group, placebo- and active-controlled Phase 2 clinical trial aimed at evaluating the efficacy, safety…
- Trial name
- NCT07109700
- Testing
- HDM1005 1, HDM1005 2, HDM1005 3
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
Japanese male and female patients with Type 2 Diabetes and aged ≥ 20 years old, with inadequate glycemic control on insulin defined as Haemoglobin A1c ≥ 7.2% and < 11% will be enrolled into the wash-out phase or directly into the…
- Trial name
- NCT02157298
- Testing
- Dapagliflozin 5 mg
- Where
- 14 sites in Japan
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose…
- Trial name
- NCT06260722
- Testing
- Retatrutide, Semaglutide
- Where
- 77 sites in United States, Argentina and 3 more
- Volunteers
- 1,250 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)
After 24 weeks of treatment evaluate the efficacy and security.
- Trial name
- NCT00832390
- Testing
- sitagliptin phosphate
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes, High Blood Sugar
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
This is a 24-week randomised, multi-centre phase III study to evaluate the efficacy and safety of dapagliflozin as monotherapy in Japanese subjects with Type 2 diabetes mellitus who have inadequate glycemic control with diet and…
- Trial name
- NCT01294423
- Testing
- Dapagliflozin
- Where
- 26 sites in Japan
- Volunteers
- 261 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment as add-on therapy to metformin in…
- Trial name
- NCT01215097
- Testing
- Linagliptin
- Where
- 19 sites in China, Malaysia and 1 more
- Volunteers
- 306 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Dose-Range Finding Study for MK0893 (0893-008)
A study to compare MK0893 to metformin or placebo for patients with Type 2 diabetes (Diabetes Mellitus).
- Trial name
- NCT00479466
- Testing
- MK0893, Metformin
- Volunteers
- 342 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus (T2DM)
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet…
- Trial name
- HDNO-1605 (NCT06647550)
- Testing
- HD-6277 100mg, HD-6277 50mg, HD-6277 25mg
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Hyundai Pharm